• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

器官间串扰揭示了 MAFLD 和肝外疾病之间不可避免的联系。

The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases.

机构信息

Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.

Department of Orthopedics, School of Medicine, Kurume University, Kurume 830-0011, Japan.

出版信息

Nutrients. 2023 Feb 23;15(5):1123. doi: 10.3390/nu15051123.

DOI:10.3390/nu15051123
PMID:36904122
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10005526/
Abstract

Fatty liver is known to be associated with extra-hepatic diseases including atherosclerotic cardiovascular disease and extra-hepatic cancers, which affect the prognosis and quality of life of the patients. The inter-organ crosstalk is mediated by metabolic abnormalities such as insulin resistance and visceral adiposity. Recently, metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed as a new definition for fatty liver. MAFLD is characterized by the inclusion criteria of metabolic abnormality. Therefore, MAFLD is expected to identify patients at high risk of extra-hepatic complications. In this review, we focus on the relationships between MAFLD and multi-organ diseases. We also describe the pathogenic mechanisms of the inter-organ crosstalk.

摘要

脂肪肝与包括动脉粥样硬化性心血管疾病和肝外癌症在内的肝外疾病有关,这些疾病会影响患者的预后和生活质量。器官间的串扰是由代谢异常介导的,如胰岛素抵抗和内脏肥胖。最近,代谢相关脂肪性肝病(MAFLD)被提出作为脂肪肝的一个新定义。MAFLD 的特点是包括代谢异常的纳入标准。因此,MAFLD 有望识别出有肝外并发症高风险的患者。在这篇综述中,我们重点讨论了 MAFLD 与多器官疾病之间的关系。我们还描述了器官间串扰的发病机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3b/10005526/540b1516f756/nutrients-15-01123-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3b/10005526/18a1cb8e3cac/nutrients-15-01123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3b/10005526/84c2b48dc104/nutrients-15-01123-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3b/10005526/8acb0f250dce/nutrients-15-01123-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3b/10005526/540b1516f756/nutrients-15-01123-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3b/10005526/18a1cb8e3cac/nutrients-15-01123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3b/10005526/84c2b48dc104/nutrients-15-01123-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3b/10005526/8acb0f250dce/nutrients-15-01123-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c3b/10005526/540b1516f756/nutrients-15-01123-g004.jpg

相似文献

1
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases.器官间串扰揭示了 MAFLD 和肝外疾病之间不可避免的联系。
Nutrients. 2023 Feb 23;15(5):1123. doi: 10.3390/nu15051123.
2
MAFLD as part of systemic metabolic dysregulation.MAFLD作为全身代谢失调的一部分。
Hepatol Int. 2024 Oct;18(Suppl 2):834-847. doi: 10.1007/s12072-024-10660-y. Epub 2024 Apr 9.
3
Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.代谢相关脂肪性肝病:新命名及其影响。
World J Gastroenterol. 2023 Jan 21;29(3):549-560. doi: 10.3748/wjg.v29.i3.549.
4
Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease.代谢综合征与代谢相关脂肪性肝病的关系。
Trends Endocrinol Metab. 2021 Jul;32(7):500-514. doi: 10.1016/j.tem.2021.04.008. Epub 2021 May 8.
5
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.肥胖的病理生理分子机制:MAFLD 和 NASH 与心血管疾病的联系。
Int J Mol Sci. 2021 Oct 27;22(21):11629. doi: 10.3390/ijms222111629.
6
The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.代谢功能障碍相关脂肪性肝病的进展和消退与亚临床动脉粥样硬化的发生有关:一项前瞻性分析。
Metabolism. 2021 Jul;120:154779. doi: 10.1016/j.metabol.2021.154779. Epub 2021 Apr 23.
7
Lean Metabolic-Associated Fatty Liver Disease.Lean 代谢相关性脂肪性肝病。
Endocrinol Metab Clin North Am. 2023 Sep;52(3):431-444. doi: 10.1016/j.ecl.2023.02.003. Epub 2023 Mar 21.
8
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.非酒精性脂肪性肝病或代谢相关脂肪性肝病诊断与心血管疾病:从流行病学到药物治疗方法。
Eur J Clin Invest. 2021 Jul;51(7):e13519. doi: 10.1111/eci.13519. Epub 2021 Mar 2.
9
MAFLD: Renovation of clinical practice and disease awareness of fatty liver.代谢相关脂肪性肝病:临床实践的革新与脂肪肝疾病认知
Hepatol Res. 2022 May;52(5):422-432. doi: 10.1111/hepr.13706. Epub 2021 Sep 17.
10
Metabolic-Associated Fatty Liver Disease: A Disastrous Human Health Challenge.代谢相关脂肪性肝病:人类健康的灾难性挑战。
Endocrinol Metab Clin North Am. 2023 Sep;52(3):xv-xvi. doi: 10.1016/j.ecl.2023.03.001. Epub 2023 Mar 22.

引用本文的文献

1
Metabolic dysfunction-associated fatty liver disease (MAFLD) in the adult population attending a health check-up program in Thailand: prevalence and fibrosis status.泰国参加健康检查项目的成年人群中代谢功能障碍相关脂肪性肝病(MAFLD):患病率及纤维化状况
Sci Rep. 2025 Jul 1;15(1):21429. doi: 10.1038/s41598-025-06874-1.
2
Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia.解析代谢相关脂肪性肝病(MAFLD)与肌肉减少症之间的代谢途径
Int J Mol Sci. 2025 May 14;26(10):4673. doi: 10.3390/ijms26104673.
3
Role of metabolic dysfunction-associated fatty liver disease in atrial fibrillation and heart failure: molecular and clinical aspects.

本文引用的文献

1
Discovery of a novel, liver-targeted thyroid hormone receptor-β agonist, CS271011, in the treatment of lipid metabolism disorders.新型肝靶向甲状腺激素受体-β激动剂 CS271011 治疗脂代谢紊乱的研究发现。
Front Endocrinol (Lausanne). 2023 Jan 20;14:1109615. doi: 10.3389/fendo.2023.1109615. eCollection 2023.
2
Metabolic associated fatty liver disease and bone mineral density: a cross-sectional study of the National Health and Nutrition Examination Survey 2017-2018.代谢相关脂肪性肝病与骨密度:一项基于2017 - 2018年美国国家健康与营养检查调查的横断面研究
Osteoporos Int. 2023 Apr;34(4):713-724. doi: 10.1007/s00198-023-06687-w. Epub 2023 Jan 31.
3
代谢功能障碍相关脂肪性肝病在心房颤动和心力衰竭中的作用:分子与临床层面
Front Cardiovasc Med. 2025 Apr 8;12:1573841. doi: 10.3389/fcvm.2025.1573841. eCollection 2025.
4
Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.通过加权基因共表达网络分析(WGCNA)和套索回归(LASSO)鉴定并验证了慢性阻塞性肺疾病(COPD)合并非酒精性脂肪性肝炎(NASH)的免疫相关诊断指标和靶向治疗方法。
Front Immunol. 2025 Feb 28;16:1514422. doi: 10.3389/fimmu.2025.1514422. eCollection 2025.
5
Neuro-Nutrition and Exercise Synergy: Exploring the Bioengineering of Cognitive Enhancement and Mental Health Optimization.神经营养与运动协同作用:探索认知增强和心理健康优化的生物工程学
Bioengineering (Basel). 2025 Feb 19;12(2):208. doi: 10.3390/bioengineering12020208.
6
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.代谢(功能障碍)相关脂肪性肝病指标及其对肝脏研究的贡献。
Hepatol Int. 2024 Dec;18(6):1740-1755. doi: 10.1007/s12072-024-10731-0. Epub 2024 Oct 16.
7
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.代谢功能障碍相关脂肪性肝病与心血管风险:全面综述。
Cardiovasc Diabetol. 2024 Sep 28;23(1):346. doi: 10.1186/s12933-024-02434-5.
8
Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults.成年人中肝脂肪变性和肝纤维化与慢性阻塞性肺疾病的相关性。
Sci Rep. 2024 May 11;14(1):10822. doi: 10.1038/s41598-024-61696-x.
9
Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment.肥胖的临床分类及其对代谢功能障碍相关脂肪性肝病和治疗的影响
Diabetes Metab Syndr Obes. 2023 Oct 25;16:3303-3329. doi: 10.2147/DMSO.S431251. eCollection 2023.
10
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.代谢相关脂肪性肝病(MAFLD)发病机制的新见解:肠-肝-心轴的相互作用
Nutrients. 2023 Sep 14;15(18):3970. doi: 10.3390/nu15183970.
Impact of Thyroid Function on the Prevalence and Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease.
甲状腺功能对代谢相关脂肪性肝病患病率和死亡率的影响。
J Clin Endocrinol Metab. 2023 Jun 16;108(7):e434-e443. doi: 10.1210/clinem/dgad016.
4
Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease.甲状腺功能低下与代谢功能障碍相关脂肪性肝病患者发生晚期纤维化的风险增加有关。
BMC Gastroenterol. 2023 Jan 5;23(1):3. doi: 10.1186/s12876-022-02612-3.
5
Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities.基于代谢/血糖异常分层的代谢相关脂肪性肝病的脂肪肝和代谢标志物的诊断能力。
J Diabetes Investig. 2023 Mar;14(3):463-478. doi: 10.1111/jdi.13966. Epub 2022 Dec 25.
6
Serum metabolomics-based heterogeneities and screening strategy for metabolic dysfunction-associated fatty liver disease (MAFLD).基于血清代谢组学的代谢功能障碍相关脂肪性肝病(MAFLD)的异质性及筛查策略
Clin Chim Acta. 2023 Jan 1;538:203-210. doi: 10.1016/j.cca.2022.12.014. Epub 2022 Dec 20.
7
Association between Metabolic Dysfunction-associated Fatty Liver Disease and Cognitive Impairment.代谢功能障碍相关脂肪性肝病与认知障碍之间的关联。
J Clin Transl Hepatol. 2022 Dec 28;10(6):1034-1041. doi: 10.14218/JCTH.2021.00490. Epub 2022 Feb 17.
8
Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach.代谢相关性脂肪性肝病患者心血管疾病的危险因素:一种机器学习方法。
Cardiovasc Diabetol. 2022 Nov 12;21(1):240. doi: 10.1186/s12933-022-01672-9.
9
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.每周一次皮下注射司美格鲁肽可改善 2 型糖尿病患者的脂肪肝疾病:一项为期 52 周的前瞻性真实世界研究。
Nutrients. 2022 Nov 4;14(21):4673. doi: 10.3390/nu14214673.
10
The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.代谢相关脂肪性肝病与无症状韩国人群中低肌肉量的关系。
J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2953-2960. doi: 10.1002/jcsm.13099. Epub 2022 Oct 12.